Madhuri Bajaj

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

Olanzapine for the Prevention of Chemotherapy-Induced Nausea and Vomiting

Rudolph M. Navari, Rui Qin, Kathryn J. Ruddy et al. · New England Journal of Medicine · 2016 · 450 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +14

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced <i>BRAF</i>-Mutant Melanoma: The DREAMseq Trial—ECOG-ACRIN EA6134

Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski et al. · Journal of Clinical Oncology · 2022 · 439 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17

Ramucirumab with cisplatin and fluoropyrimidine as first-line therapy in patients with metastatic gastric or junctional adenocarcinoma (RAINFALL): a double-blind, randomised, placebo-controlled, phase 3 trial

Charles S. Fuchs, Kohei Shitara, Maria Di Bartolomeo et al. · The Lancet Oncology · 2019 · 284 citations · Full text

Medicine, Oncology, Pharmacology +13

Pembrolizumab Plus Ipilimumab Following Anti-PD-1/L1 Failure in Melanoma

Daniel J. Olson, Zeynep Eroglu, Bruce Brockstein et al. · Journal of Clinical Oncology · 2021 · 220 citations · Full text

Pharmacy, Oncology, Pharmacotherapy +17